Updates ·
Health notices · Saturday 24 October
3 notices from the agencies today, in plain words, each with the original linked.
WHO reports expanding Bundibugyo virus Ebola outbreak
World Health Organization (WHO) · Outbreak
If you are in the Democratic Republic of the Congo, or you have recently been in contact with someone who travelled there, this update matters because sustained, high-level transmission continues.
In Kenya and Nigeria, WHO reports imported cases; Kenya has nine cases total (including one death), and Nigeria has an imported case in isolation. WHO says there is currently no evidence of wider community transmission in those countries.
WHO also advises against any restriction of travel to, or trade with, affected countries. The update highlights ongoing needs for early case detection and timely access to appropriate care.
What to do
- WHO advises against any restriction of travel to, or trade with, affected countries.
Class II issue reported for fosfomycin granules
FDA · Recall
If you have been prescribed fosfomycin tromethamine granules for oral solution, the US FDA has reported a Class II issue with this product.
The concern described is “failed impurities/degradation specifications,” meaning the product did not meet required purity/stability quality standards.
No patient actions or specific return instructions are provided in this notice. Check what your pharmacist or prescriber advises about continuing or obtaining your dose.
FDA approval for methylphenidate hydrochloride for pediatric ADHD
FDA · Approval
If your child is 6 to 15 years old and has attention deficit hyperactivity disorder (ADHD), the US Food and Drug Administration has approved methylphenidate hydrochloride extended-release capsules for treatment.
Methylphenidate hydrochloride is a central nervous system (CNS) stimulant, meaning it affects the brain and nerves. The label says it is not recommended for children younger than 6 due to higher exposure and more adverse reactions.
Tomorrow, your care team may have this approved treatment option to consider for eligible children; dosing decisions are made based on your child’s health needs and the full prescribing information.